TAES for FPVCs: a Pragmatic, Randomized Controlled Trial

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Premature Ventricular Complexes

In brief

This prospective, randomized controlled trial aims to evaluate the efficacy and safety of Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS) for patients with frequent premature ventricular coomplexes (FPVCs). Ninety participants will be randomized to TAVNS group and sham-TAVNS group with the ratio of 1:1. They will receive TAVNS plus usual care or sham-TAVNS plus usual care for 6 weeks, and then be followed up for 12 weeks after the treatment. The primary outcome was the proportion of participants with a 50% decrease of the 24 hour (24h) premature ventricular complexes (PVCs) after 6-week treatment. Secondary outcomes include the proportion of participants with a 75% decrease of the 24h-PVCs; the decrease from baseline of 24h-PVCs, total 24h-heartbeat, and the frequency of supraventricular arrhythmia; the score change from baseline in PVCs-related symptoms; the score change from baseline in SAS and SDS. Subgroup analyses will be performed in age, gender, and the severity of PVCs. Safety assessment will be documented during the whole trial.

Key facts

Study ID: NCT04415203
Run by: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
People needed: 90
Starts: 2020-06-04
Expected to finish: 2025-12-01
Last updated by the study team: 2025-07-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Diagnosed as frequent premature ventricular contractions;
2 ≤ Lown level ≤ 4A;
18 ≤ age ≤ 75;
Volunteered to participant

You may not qualify if…

Severe valvular disease, congenital heart disease, pericardial disease, hypertrophic cardiomyopathy, unstable angina pectoris, acute myocardial infarction, myocarditis, aneurysm, congestive heart failure decompensation period (NYHA grade III or VI), cardiogenic shock, cerebrovascular disease, hematopoietic system disease, severe mental disease;
Bradycardia, including pathologic sinus node syndrome, degree II or greater atrioventricular block;
Those who have already had pacemaker or percutaneous coronary intervention, or who plan to have pacemaker or percutaneous coronary intervention;
Pregnant or lactating women;
Local sensory deficit, or allergic to current;
May be allergic to percutaneous patches；
Blood pressure ≤ 90/60 mmHg;
Those who have participated in other clinical trials within 3 months.

Where it is running

Guang'anmen Hospita, China Academy of Chinese Medical Sciences — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.